Printer Friendly

AstraZeneca reports detailed results of Lynparza from phase 111 POLO trial.

M2 EQUITYBITES-June 4, 2019-AstraZeneca reports detailed results of Lynparza from phase 111 POLO trial

(C)2019 M2 COMMUNICATIONS http://www.m2.com

AstraZeneca Plc (LON:AZN), a global, science-led biopharmaceutical company, and pharmaceutical company Merck & Co Inc (MSD Inc outside US and Canada) (NYSE:MRK) reported on Monday detailed results from the phase III POLO trial at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, US.

These results are also published, on 3 June 2019, in The New England Journal of Medicine (NEJM).

Reportedly, the POLO trial tested Lynparza (olaparib) tablets as first-line maintenance monotherapy for patients with germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas (pancreatic cancer) whose disease had not progressed following standard-of-care platinum-based 1st-line chemotherapy.

Results from the trial showed a statistically-significant and clinically -meaningful improvement in progression-free survival (PFS) for Lynparza vs. placebo, improving the time without disease progression by a median of 7.4 months for patients treated with Lynparza vs. 3.8 months for those on placebo.

Also, more than twice as many patients showed no disease progression both at one year (34% on Lynparza vs. 15% on placebo) and two years (22% vs. 10%, respectively).

According to the company, these unprecedented results raise new hope for patients that have seen little progress over a long period of time. From as early as six months after initiation, more than twice as many patients taking Lynparza lived without progression of their disease compared to those on placebo and the company is now working with regulatory authorities to bring Lynparza to patients as quickly as possible.

Lynparza, which is being jointly developed and commercialised by AstraZeneca and MSD, is approved for multiple indications in advanced ovarian cancer and metastatic breast cancer and has been used in over 20,000 patients worldwide.

In July 2017, AstraZeneca and Merck & Co Inc announced a global strategic oncology collaboration to co-develop and co-commercialise Lynparza, the world's first PARP inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for multiple cancer types. Working together, the companies will develop Lynparza and selumetinib in combination with other potential new medicines and as monotherapies. Independently, the companies will develop Lynparza and selumetinib in combination with their respective PD-L1 and PD-1 medicines.

AstraZeneca is focussed on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in the three therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Article Type:Financial report
Date:Jun 4, 2019
Words:412
Previous Article:Atomwise signs AI multi-target and multi year agreement with Lilly.
Next Article:Nouscom awarded US FDA approval for IND application for the first phase 1 clinical trial of its lead candidate NOUS-209.
Topics:

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |